Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis

Xiaoyan Chang,* Chenghao Wang,* Linyou Zhang Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linyou Zhang, Department of Thoracic Surg...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang X, Wang C, Zhang L
Format: Article
Language:English
Published: Dove Medical Press 2025-03-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/research-trends-of-tyrosine-kinase-inhibitors-in-egfr-mutated-non-smal-peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850035624527003648
author Chang X
Wang C
Zhang L
author_facet Chang X
Wang C
Zhang L
author_sort Chang X
collection DOAJ
description Xiaoyan Chang,* Chenghao Wang,* Linyou Zhang Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linyou Zhang, Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China, Tel +8615145106696, Email lyzhang@hrbmu.edu.cnBackground: This study seeks to identify research trends and hotspots concerning tyrosine kinase inhibitors (TKIs) for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) through a comprehensive bibliometric analysis.Methods: Publications on TKIs and EGFR-mutated NSCLC from 2006 to 2024 were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to visualize collaboration, keyword co-occurrences, and research trends.Results: A total of 962 articles were analyzed, authored by 7,458 researchers from 5,401 institutions across 208 countries. Wu Yi-Long was identified as the most prolific author, contributing 30 publications. AstraZeneca emerged as the industrial leader with 103 articles, while the New England Journal of Medicine was recognized as the primary journal with the highest total link strength. Keyword co-occurrence analysis revealed significant research topics including “gefitinib”, “chemotherapy”, “open label”, and “erlotinib.” Moreover, keyword burst analysis indicated notable periods of increased research focus on topics such as “osimertinib” and “liquid biopsy”, suggesting emerging trends and current hotspots in the treatment of EGFR-mutated NSCLC.Conclusion: This analysis highlights research trends on TKIs for EGFR-mutated NSCLC, emphasizing the importance of targeted therapies like gefitinib and osimertinib for future research and clinical practice enhancement.Keywords: tyrosine kinase inhibitors, non-small cell lung cancer, bibliometrics, CiteSpace, VOSviewer
format Article
id doaj-art-6c4d7082ef72460394343eeaa3c1ebef
institution DOAJ
issn 1177-8881
language English
publishDate 2025-03-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj-art-6c4d7082ef72460394343eeaa3c1ebef2025-08-20T02:57:25ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-03-01Volume 1917031719100963Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric AnalysisChang XWang CZhang LXiaoyan Chang,* Chenghao Wang,* Linyou Zhang Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linyou Zhang, Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China, Tel +8615145106696, Email lyzhang@hrbmu.edu.cnBackground: This study seeks to identify research trends and hotspots concerning tyrosine kinase inhibitors (TKIs) for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) through a comprehensive bibliometric analysis.Methods: Publications on TKIs and EGFR-mutated NSCLC from 2006 to 2024 were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to visualize collaboration, keyword co-occurrences, and research trends.Results: A total of 962 articles were analyzed, authored by 7,458 researchers from 5,401 institutions across 208 countries. Wu Yi-Long was identified as the most prolific author, contributing 30 publications. AstraZeneca emerged as the industrial leader with 103 articles, while the New England Journal of Medicine was recognized as the primary journal with the highest total link strength. Keyword co-occurrence analysis revealed significant research topics including “gefitinib”, “chemotherapy”, “open label”, and “erlotinib.” Moreover, keyword burst analysis indicated notable periods of increased research focus on topics such as “osimertinib” and “liquid biopsy”, suggesting emerging trends and current hotspots in the treatment of EGFR-mutated NSCLC.Conclusion: This analysis highlights research trends on TKIs for EGFR-mutated NSCLC, emphasizing the importance of targeted therapies like gefitinib and osimertinib for future research and clinical practice enhancement.Keywords: tyrosine kinase inhibitors, non-small cell lung cancer, bibliometrics, CiteSpace, VOSviewerhttps://www.dovepress.com/research-trends-of-tyrosine-kinase-inhibitors-in-egfr-mutated-non-smal-peer-reviewed-fulltext-article-DDDTtyrosine kinase inhibitorsnon-small cell lung cancerbibliometricscitespacevosviewer
spellingShingle Chang X
Wang C
Zhang L
Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
Drug Design, Development and Therapy
tyrosine kinase inhibitors
non-small cell lung cancer
bibliometrics
citespace
vosviewer
title Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
title_full Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
title_fullStr Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
title_full_unstemmed Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
title_short Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
title_sort research trends of tyrosine kinase inhibitors in egfr mutated non small cell lung cancer a bibliometric analysis
topic tyrosine kinase inhibitors
non-small cell lung cancer
bibliometrics
citespace
vosviewer
url https://www.dovepress.com/research-trends-of-tyrosine-kinase-inhibitors-in-egfr-mutated-non-smal-peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT changx researchtrendsoftyrosinekinaseinhibitorsinegfrmutatednonsmallcelllungcancerabibliometricanalysis
AT wangc researchtrendsoftyrosinekinaseinhibitorsinegfrmutatednonsmallcelllungcancerabibliometricanalysis
AT zhangl researchtrendsoftyrosinekinaseinhibitorsinegfrmutatednonsmallcelllungcancerabibliometricanalysis